Genmab A/S - Changes Board/Management/Auditors
02/06/2008 19:47
PR Newswire
COPENHAGEN, Denmark, June 2 /PRNewswire/ --
- Genmab Announces Appointment of David Eatwell as New Chief Financial
Officer
- Summary: Genmab Announces the Appointment of David A. Eatwell as Chief
Financial Officer.
Genmab A/S (OMX: GEN) today announced that David A. Eatwell has been
appointed Chief Financial Officer of the company. Mr. Eatwell will be
responsible for overseeing the financial and accounting activities of the
company.
David A. Eatwell, 47, joins Genmab with extensive experience and a proven
track record in leading international life science businesses, having spent
15 years working in Europe and 10 years in the US. Most recently, Mr. Eatwell
served as Chief Financial Officer of Catalent Pharma Solutions, Inc., a USD
1.8 billion leading provider of manufacturing and packaging services for the
pharmaceutical and biotech industry, with 33 facilities in 12 countries and
10,000 employees. Prior to Catalent Mr. Eatwell served as a divisional CFO of
Cardinal Health, Inc., a fortune 20 global manufacturer and distributor of
healthcare products and services, where he spearheaded the USD 3.3 billion
sale of the Pharmaceutical Technologies and Services division to The
Blackstone Group and was instrumental in creating the framework and building
the infrastructure to support the newly created company, Catalent Pharma
Solutions, Inc. Mr. Eatwell is a Chartered Accountant.
Mr. Eatwell is replacing Bo Kruse who has decided to seek new challenges
elsewhere, but will during a transitional period be available for the
company.
"We are very excited to have David Eatwell on board to be part of our
Senior Management team and we are looking forward to working with him. We
also wish to thank Bo Kruse for his many years of dedicated service to
Genmab, and important contributions to the company. We wish Bo Kruse the best
of luck in his future endeavors and would like to thank him for his efforts
at Genmab since 2000", said Lisa N. Drakeman, Ph.D., Chief Executive Officer
of Genmab.
About Genmab A/S Genmab is a leading international biotechnology company
focused on developing fully human antibody therapeutics for unmet medical
needs. Using cutting-edge antibody technology, Genmab's world class
discovery, development and manufacturing teams have created and developed an
extensive pipeline of products for potential treatment of a variety of
diseases including cancer and autoimmune disorders. As Genmab advances
towards a commercial future, we remain committed to our primary goal of
improving the lives of patients who are in urgent need of new treatment
options. For more information on Genmab's products and technology, visit
http://www.genmab.com.
This press release contains forward looking statements. The words
"believe", "expect", "anticipate", "intend" and "plan" and similar
expressions identify forward looking statements. Actual results or
performance may differ materially from any future results or performance
expressed or implied by such statements. The important factors that could
cause our actual results or performance to differ materially include, among
others, risks associated with product discovery and development,
uncertainties related to the outcome and conduct of clinical trials including
unforeseen safety issues, uncertainties related to product manufacturing, the
lack of market acceptance of our products, our inability to manage growth,
the competitive environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and proprietary rights,
our relationships with affiliated entities, changes and developments in
technology which may render our products obsolete, and other factors. Genmab
is not under an obligation to up-date statements regarding the future
following the publication of this release; nor to confirm such statements in
relation to actual results, unless this is required by law.
Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R);
HuMax-CD20(R); HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM);
HuMax-CD38(TM); HuMax-CD32b(TM) and UniBody(R) are all trademarks of Genmab
A/S.
Contact: Helle Husted, Sr. Director, Investor Relations, T: +45-33-44-77
30, M: +45-25-27-47-13, E: hth@genmab.com
Stock Exchange Release no. 27/2008
Contact: Helle Husted, Sr. Director, Investor Relations, T: +45-33-44-77 30, M: +45-25-27-47-13, E: hth@genmab.com
-